630 related articles for article (PubMed ID: 16753380)
1. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
[TBL] [Abstract][Full Text] [Related]
2. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
4. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer.
Foster RS; Baniel J; Leibovitch I; Curran M; Bihrle R; Rowland R; Donohue JP
J Urol; 1996 Jun; 155(6):1943-5. PubMed ID: 8618293
[TBL] [Abstract][Full Text] [Related]
5. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Eggener SE; Carver BS; Loeb S; Kondagunta GV; Bosl GJ; Sheinfeld J
Cancer; 2007 Feb; 109(3):528-35. PubMed ID: 17177200
[TBL] [Abstract][Full Text] [Related]
6. Presence of teratoma in orchiectomy specimen increases the need for postchemotherapy RPLND.
Inci K; Dogan HS; Akdogan B; Baydar DE; Ergen A; Ozen H
Urol Oncol; 2011; 29(1):38-42. PubMed ID: 19269199
[TBL] [Abstract][Full Text] [Related]
7. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Koch MO; Wahle GR; Donohue JP
J Urol; 2001 May; 165(5):1517-20. PubMed ID: 11342909
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
9. Clinical and pathological features predictive of nephrectomy at post-chemotherapy retroperitoneal lymph node dissection.
Cary KC; Beck SD; Bihrle R; Foster RS
J Urol; 2013 Mar; 189(3):812-7. PubMed ID: 23017517
[TBL] [Abstract][Full Text] [Related]
10. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
Peterson M; Beck S; Bihrle R; Einhorn L; Foster R
BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258
[TBL] [Abstract][Full Text] [Related]
11. Germ cell tumor associated primitive neuroectodermal tumors.
Ganjoo KN; Foster RS; Michael H; Donohue JP; Einhorn LH
J Urol; 2001 May; 165(5):1514-6. PubMed ID: 11342908
[TBL] [Abstract][Full Text] [Related]
12. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
Beck SD; Foster RS; Bihrle R; Ulbright T; Koch MO; Wahle GR; Einhorn LH; Donohue JP
J Urol; 2002 Oct; 168(4 Pt 1):1402-4. PubMed ID: 12352402
[TBL] [Abstract][Full Text] [Related]
13. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer.
Williams SB; Steele GS; Richie JP
J Urol; 2009 Dec; 182(6):2716-20. PubMed ID: 19836777
[TBL] [Abstract][Full Text] [Related]
14. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
15. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
Mosharafa AA; Foster RS; Leibovich BC; Bihrle R; Johnson C; Donohue JP
J Urol; 2003 Jun; 169(6):2126-8. PubMed ID: 12771733
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
Stephenson AJ; Tal R; Sheinfeld J
J Urol; 2006 Nov; 176(5):1996-9; discussion 1999. PubMed ID: 17070234
[TBL] [Abstract][Full Text] [Related]
17. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
18. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.
Nash PA; Leibovitch I; Foster RS; Bihrle R; Rowland RG; Donohue JP
J Urol; 1998 Mar; 159(3):707-10. PubMed ID: 9474130
[TBL] [Abstract][Full Text] [Related]
19. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
Williams SB; Kacker R; Steele GS; Richie JP
Urol Oncol; 2012; 30(1):60-3. PubMed ID: 20189842
[TBL] [Abstract][Full Text] [Related]
20. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
